Patents by Inventor Tyvin A. Rich

Tyvin A. Rich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230384335
    Abstract: Apparatus and method for acquiring and analyzing biological samples are provided. The apparatus may be in the form of a free-standing apparatus, and include: means for receipt of identifying data of the individual; means for receiving the biological sample for the individual; means for providing a unique identifier for the biological sample and association with the individual; and means for conducting an analysis of the biological sample and generating a report of analysis results; wherein all of the foregoing means are under control of a microprocessor located in the apparatus. The apparatus and method allow fast processing of samples.
    Type: Application
    Filed: April 6, 2023
    Publication date: November 30, 2023
    Inventors: David Lyle SCHNEIDER, Tyvin A. RICH, Martin A. ATWOOD
  • Publication number: 20230010671
    Abstract: The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18O to 18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18O have been made and tested.
    Type: Application
    Filed: June 27, 2022
    Publication date: January 12, 2023
    Applicants: UNIVERSITY OF VIRGINIA PATENT FOUNDATION, HAMPTON UNIVERSITY
    Inventors: Tyvin A. RICH, Dongfeng PAN, Mahendra D. CHORDIA
  • Patent number: 11396523
    Abstract: The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18O to 18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18O have been made and tested.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: July 26, 2022
    Assignees: University of Virginia Patent Foundation, Hampton University
    Inventors: Tyvin A. Rich, Dongfeng Pan, Mahendra D. Chordia
  • Publication number: 20210024564
    Abstract: The present application provides compositions and methods for preparing and using “heavy” nucleotide derivatives of thymidine or uridine by replacing the oxygen atom attached to one or more of positions with non-radioactive oxygen-18 (18O), administering it to a subject to target a tumor including incorporation into tumor cell DNA, and then treating the tumor with proton beam therapy to transmutate the 18O to 18F, resulting in a break of the new fluorine-phosphorous bond. This chemical event destabilizes ribose-phosphate DNA back-bone and base pairing thus produce single- and double strand breaks, clusters lesions that can lead to irreparable DNA damage and enhanced tumor cell killing. The atomic, chemical, and physical aspects result in the use of lower radiation doses and significantly alter acute and late morbidity of radiotherapy. Heavy thymidine and heavy uridine derivatives labeled with 18O have been made and tested.
    Type: Application
    Filed: June 22, 2018
    Publication date: January 28, 2021
    Inventors: Tyvin A. Rich, Dongfeng Pan, Mahendra D. Chordia
  • Patent number: 6099821
    Abstract: A method is provided for assessing the functional integrity of a mucosal membrane, comprising: (a) locally administering a dosage of a radionuclide to the surface of a mucosal membrane of a mammal; and (b) employing dynamic scintigraphy to measure the absorption of the radionuclide into the bloodstream of the mammal.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: August 8, 2000
    Assignees: University of Virginia, University of Virginia Patent Foundation
    Inventors: Tyvin A. Rich, Alexander V. Kirichenko